Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis / Hélène Haguet, Jonathan Douxfils, François Mullier, Christian Chatelain, Carlos Graux, Jean-Michel Dogné
ABSTRACT Background : A previous meta-analysis demonstrated that 3 of the new-generation BCR-ABL tyrosine kinase inhibitors (TKIs) (dasatinib, nilotinib and ponatinib) are associated with an increased risk of vascular occlusive events in patients with Ph+ chronic myeloid leukemia compared with imatinib. This meta-analysis of randomized controlled trials aims at assessing these risks separately. Methods : The literature search was performed by two independent reviewers following the previous protocol (PROSPERO 2014:CRD42014014147). A random-effects model and a fixed-effect model were used according to the characteristics of the included studies. Peto odds ratios with 95%CI were computed. Results : Overall, 4.78% of patients developed arterial occlusive events with new generation TKIs compared with 0.96% with imatinib. Ponatinib (OR PETO :3.26; 95%CI:1.12 to 9.50), nilotinib (OR PETO : 3.69; 95%CI:2.29 to 5.95) and dasatinib (OR PETO :3.32; 95%CI:1.37 to 8.01) are all associated with a higher risk of arterial occlusive events than imatinib. Venous occlusive events occur in 0.72% of patients treated with new generation TKIs and in 0.27% of imatinib-treated patients. Overall, a trend toward an increase of the rate of venous occlusive events with new-generation TKIs (OR PETO :2.17; 95%CI:0.90 to 5.25) was highlighted but stratifications by treatment gave nonsignificant results. Conclusions : Vascular occlusive events associated with new-generation BCR-ABL TKIs are driven by arterial occlusive events.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Expert opinion on drug safety - 16(2017), 1, Seite 5- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Haguet, Hélène [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (8 p) |
|---|
| doi: |
10.1080/14740338.2017.1261824 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL001113828 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL001113828 | ||
| 003 | DE-627 | ||
| 005 | 20230623202327.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210608s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14740338.2017.1261824 |2 doi | |
| 035 | |a (DE-627)KFL001113828 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/14740338.2017.1261824 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Haguet, Hélène |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis |c Hélène Haguet, Jonathan Douxfils, François Mullier, Christian Chatelain, Carlos Graux, Jean-Michel Dogné |
| 264 | 1 | |c 2017 | |
| 300 | |a 1 Online-Ressource (8 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Background : A previous meta-analysis demonstrated that 3 of the new-generation BCR-ABL tyrosine kinase inhibitors (TKIs) (dasatinib, nilotinib and ponatinib) are associated with an increased risk of vascular occlusive events in patients with Ph+ chronic myeloid leukemia compared with imatinib. This meta-analysis of randomized controlled trials aims at assessing these risks separately. Methods : The literature search was performed by two independent reviewers following the previous protocol (PROSPERO 2014:CRD42014014147). A random-effects model and a fixed-effect model were used according to the characteristics of the included studies. Peto odds ratios with 95%CI were computed. Results : Overall, 4.78% of patients developed arterial occlusive events with new generation TKIs compared with 0.96% with imatinib. Ponatinib (OR PETO :3.26; 95%CI:1.12 to 9.50), nilotinib (OR PETO : 3.69; 95%CI:2.29 to 5.95) and dasatinib (OR PETO :3.32; 95%CI:1.37 to 8.01) are all associated with a higher risk of arterial occlusive events than imatinib. Venous occlusive events occur in 0.72% of patients treated with new generation TKIs and in 0.27% of imatinib-treated patients. Overall, a trend toward an increase of the rate of venous occlusive events with new-generation TKIs (OR PETO :2.17; 95%CI:0.90 to 5.25) was highlighted but stratifications by treatment gave nonsignificant results. Conclusions : Vascular occlusive events associated with new-generation BCR-ABL TKIs are driven by arterial occlusive events | ||
| 700 | 1 | |a Douxfils, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Mullier, François |e verfasserin |4 aut | |
| 700 | 1 | |a Chatelain, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Graux, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Dogné, Jean-Michel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug safety |d Abingdon, Oxon : Routledge, Taylor & Francis, 2002 |g 16(2017), 1, Seite 5- |h Online-Ressource |w (DE-627)KFL000006084 |w (DE-600)2114527-1 |w (DE-576)302969721 |x 1744-764X |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2017 |g number:1 |g pages:5- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/14740338.2017.1261824 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_LgpH_01 | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2017 |e 1 |h 5- | ||